Uracyst

Type: Product
Name: Uracyst
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Why Does This Former Pharma King Keep Buying Shares Of Tribute Pharmaceuticals ?

SummaryFollowing John Gregory's lead has proven to be prosperous. Bringing Bezalip to the U.S. adds enormous potential. Prescriptions for Cambia rose over 30% YOY.From registered pharmacist to CEO of a pharmaceutical giant, John Gregory has shown that ... [Published Seeking Alpha - Apr 09 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

(MKTW) Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth

Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future GrowthMILTON, ONTARIO--(Marketwired - Mar 31, 2014) - Tribute Pharmaceuticals Canada Inc . (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), ... [Published Scottrade - Mar 31 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Tribute Pharmaceuticals Schedules 2013 Year End Financial Results Conference Call

MILTON, ONTARIO -- (Marketwired) -- 03/25/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare ... [Published PR inside - Mar 25 2014]

Quotes

"Due to the limited availability of approved therapies, the current line of treatment is dominated by off-label drug options such as antidepressants (amitriptyline), antihistamines (hydroxyzine), analgesics (opioid and non-steroidal) and others. The IC therapeutics market is predicted to experience static growth during the forecast period, primarily due to the limited availability of approved products, low diagnosis rate, and lack of new product approvals during this period."
Wolfgang Stoiber of JSB Partners stated, "We are excited to be working with Tribute Pharmaceuticals on establishing a potential late stage development and future marketing partnership with another pharmaceutical company for their product Bezalip SR. Over the last 15 years we have helped numerous bio-pharmaceutical companies develop partnerships and joint ventures for their respected products and look forward to the possibility of completing a transaction on Bezalip SR"

More Content

All (3) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Why Does This Former Pharma King Keep Buying Sh... [Published Seeking Alpha - Apr 09 2014]
(MKTW) Tribute Pharmaceuticals Reports Full Yea... [Published Scottrade - Mar 31 2014]
Tribute Pharmaceuticals Schedules 2013 Year End... [Published PR inside - Mar 25 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.